DEEP RESEARCH · HANMI PHARM
Hanmi Pharm: R&D Transition and Commercial Scalability
A company review of 3Q 2025 results, the domestic ETC base, obesity programs, and oncology pipeline
0. Bottom line first
My view is that Hanmi Pharm funds R&D with a durable domestic prescription-drug base. The key question is whether cash cows such as Rosuzet and the Amosartan family are strong enough to carry the long development timelines of the H.O.P obesity pipeline and oncology assets.
1. Industry setting and Hanmi’s position
Official fact: The source cites a global obesity-treatment market reaching around KRW 106 trillion, or USD 77 billion, near 2030. It also cites Korea’s 2023 pharmaceutical production at about KRW 31 trillion, with 5.3% CAGR over the prior five years.
Interpretation: The GLP-1-led metabolic-disease boom is favorable for Hanmi’s LAPSCOVERY and H.O.P strategy. But obesity is also one of the most competitive areas against global big pharma.
2. Corporate structure
Since the 2010 spin-off, Hanmi Pharm has operated under Hanmi Science. The source states that as of the end of September 2025, Hanmi Science owned 41.42% of Hanmi Pharm and was the largest shareholder.
Beijing Hanmi
Founded in 1996, with Chinese pediatric-drug brands and integrated R&D, manufacturing, and sales capabilities.
Hanmi Fine Chemical
Trying to move from cephalosporin APIs into higher-value CDMO areas such as mRNA raw materials and LNPs.
Online Pharm
Provides an owned channel in Korea’s changing pharmaceutical distribution market.
3. Commercial base: prescription sales as defense
The source lists 2024 outpatient prescription sales of KRW 210.3 billion for Rosuzet (+17.6%), KRW 146.7 billion for the Amosartan family (+3.3%), and KRW 65.2 billion for the Esomezol family (+1.5%). These figures show that Hanmi is not only a pipeline story but also has a real prescription-drug base.
| Product | Indication | 2024 sales | Growth | Meaning |
|---|---|---|---|---|
| Rosuzet | Dyslipidemia | KRW 210.3bn | +17.6% | No. 1 Korean prescription drug |
| Amosartan family | Hypertension | KRW 146.7bn | +3.3% | Combination-drug line expansion |
| Esomezol family | GERD | KRW 65.2bn | +1.5% | PPI product base |
4. R&D: obesity and oncology options
Official fact: The source says Hanmi has built metabolic-disease capabilities through LAPSCOVERY and is developing a full-cycle obesity pipeline through the H.O.P project. It also lists oncology candidates including an EZH1/2 inhibitor, tuspetinib, and BH3120.
Interpretation: Hanmi’s advantage is that it is not dependent on a single candidate. The drawback is that investors must track many clinical, commercial, and governance variables at once.
5. Checklist
- Prescription growth for Rosuzet and the Amosartan family
- Beijing Hanmi’s China revenue and R&D contribution
- Hanmi Fine Chemical’s recovery from API pressure and CDMO transition
- Clinical data and licensing potential for the H.O.P obesity pipeline
- Global clinical progress in oncology assets
Sources
- Original post: https://m.blog.naver.com/PostView.naver?blogId=star_of_self&logNo=224092042366
- Hanmi Pharm 3Q 2025 IR material and quarterly report reconstruction: cited in source post